



RealRate

PHARMACEUTICAL 2022











PHARMACEUTICAL 2022



NextCure Inc. Rank 58 of 466



The relative strengths and weaknesses of NextCure Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NextCure Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 55% points. The greatest weakness of NextCure Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 264%, being 186% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	227,817
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,608
Liabilities, Non-Current	0
Other Assets	577
Other Compr. Net Income	-1,442
Other Expenses	0
Other Liabilities	2,392
Other Net Income	1,376
Other Revenues	0
Property and Equipment	13,992
Research and Development	50,192
Selling, General and Administrative Expense	20,573

Output Variable	Value in 1000 USD
Assets	242,386
Liabilities	9,000
Expenses	70,765
Revenues	0
Stockholders Equity	233,386
Net Income	-69,389
Comprehensive Net Income	-70,110
Economic Capital Ratio	264%

